Variation in Care Improvement Opportunities Suggests Need for Tailored Clinician-Specific Improvement Interventions

Similar documents
Health Care Systems Research Network (HCSRN) Conference April 12, 2018 Minneapolis, MN

Diagnosis and Management of Type 2 Diabetes Mellitus in Adults

Hypertension in 2015: SPRINT-ing ahead of JNC-8. MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic

Blue Shield Participation

Disclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease

The Latest Generation of Clinical

How Doctors Choose Medicines when Treating Patients with Type 2 Diabetes

WELL-WOMAN EXAM REVEALS RISK. Katie Jones, MPH, CHES Iowa Department of Public Health Erin Hinderaker, MS, RD, LD Des Moines University

Best Practices in Cardiac Care: Getting with the Guidelines

Crossing The Quality Chasm: Cardiovascular Care

Management of Lipid Disorders and Hypertension: Implications of the New Guidelines

SAGE. Nick Beard Vice President, IDX Systems Corp.

COMMUNITY EFFORTS TO PREVENT TYPE 2 DIABETES

Wisconsin Chronic Disease Quality Improvement Project. HEDIS 2017 Summary Data

Electronic Documentation of Lifestyle Counseling and Glycemic Control in Patients with Diabetes

Update on New RCHC Relevant and BridgeIT Reports. Redwood Community Health Coalition Data Group Webinar November 13, 2018 By Ben Fouts, Data Analyst

American Diabetes Association 2018 Guidelines Important Notable Points

Disclosure. No relevant financial relationships. Placebo-Controlled Statin Trials

Disclosures. Objectives. Cardiovascular Risk. Patient Case. JUPITER: The final frontier in statin utilization or an idea from outer space?

CORONARY ARTERY DISEASE (CAD) MEASURES GROUP OVERVIEW

Update in Hypertension

Guidelines to assist General Practitioners in the Management of Type 2 Diabetes. April 2010

Diabetes Care begins with Diabetes Prevention. Neha Sachdev, MD Janet Williams, MA

Val-MARC: Valsartan-Managing Blood Pressure Aggressively and Evaluating Reductions in hs-crp

Donna Amundson, RN, BSN, CDE Director of the Sanford Diabetes Center Bismarck, ND

Management of DM in Older Adults: It s not all about sugar! Who needs treatment for DM? Peggy Odegard, Pharm.D., BCPS, CDE

HEALTH SERVICES POLICY & PROCEDURE MANUAL

Beyond 2018: Sharing Million Hearts Lessons and Road Rash. Building the Bridge Beyond 2018 National Colorectal Cancer Round Table December 7, 2017

Preventing 1 Million Heart Attacks and Strokes by 2022

JNC Evidence-Based Guidelines for the Management of High Blood Pressure in Adults

VA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005

MODERN MANAGEMENT OF HYPERTENSION Where Do We Draw the Line? Disclosure. No relevant financial relationships. Blood Pressure and Risk

Quality Care Plus 2015 Primary Care Physician Incentive Program. Now includes Medicare patients!

Adult Diabetes Clinician Guide NOVEMBER 2017

ESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES

PCMH 2018 Enrollment and Update August 25, 2017

Preventing and Addressing Chronic Disease. Tim Nikolai, Sr. Community Health Director

Managing Hypertension in 2016

Finding the sweet spot: Individualized targets for older adults with Type 2 DM

RCCO Quality Indicators Crosswalk

ADVANCES IN MANAGEMENT OF HYPERTENSION

Diabetes: Use of Adjunctive Therapy ACEs, ARBs, ASA & STATINs --Oh My! Veronica J. Brady, PhD, FNP-BC, BC-ADM, CDE Project ECHO April 19, 2018

Diabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable?

Translating the KidneyWise Clinical Toolkit into an Electronic Medical Record Decision Support Tool

May 2016 CTC/OHIC Measure Specifications

Lipid Management 2013 Statin Benefit Groups

New Recommendations for the Treatment of Hypertension: From Population Salt Reduction to Personalized Treatment Targets

Difficult-to-Control & Resistant Hypertension. Anthony Viera, MD, MPH, FAHA Professor and Chair

Dissemination and Implementation Research in Diabetes and Obesity. Christine Hunter National Institute of Diabetes and Digestive and Kidney Diseases

Pharmacy Partnership to Improve Patient Outcomes

A Practical Approach to the Use of Diabetes Medications

MANAGEMENT OF HYPERTENSION: TREATMENT THRESHOLDS AND MEDICATION SELECTION

Diabetes Care begins with Diabetes Prevention. Neha Sachdev, MD Janet Williams, MA

American Diabetes Association Standards of Medical Care in Diabetes 2018: Latest Updates

Measure Up/Pressure Down Medical Group Success

The Ontario Drug Policy Research Network: Generating Evidence to Inform Policy

When Statins Aren t Enough: Appropriate Therapies for High-Risk Patients with Diabetes

Diabetic Nephropathy

New Hypertension Guidelines. Kofi Osei, MD

RISK FACTORS OR COMPLICATIONS AND RECOMMENDED TREATMENT GOALS AND FREQUENCY OF EVALUATION FOR ADULTS WITH DIABETES

CVD Risk Assessment. Michal Vrablík Charles University, Prague Czech Republic

HEDIS 2014 MQIC MEASURES SUMMARY LISTING FOR ANNUAL PERFORMANCE REPORTING

Boosting the Value of Lab Testing: How HEDIS Uses Lab

WCHQ MEASURES AT A GLANCE

Section 1: 1: Trends. Section 2: 2: Comparisons to to Overall Portland Area Area Results for for

The Diabetes Link to Heart Disease

DIABETES MEASURES GROUP OVERVIEW

9/18/2017 DISCLOSURES. Consultant: RubiconMD. Research: Amgen, NHLBI OUTLINE OBJECTIVES. Review current CV risk assessment tools.

Driving Outcomes By Scaling Population Health Management

Presentation title. Better Health Care For Greater Cleveland Learning Collaborative March 5, Ron Adams, MD Regional Chief Internal Medicine

Working Together to Prevent Diabetes

ADVANCES IN MANAGEMENT OF HYPERTENSION

Diabetes Complications Guideline Based Screening, Management, and Referral

Top 5 (Topics) Papers In GIM Rocky Mountain ACP Internal Medicine Meeting Raj Padwal November 13, 2008

Layered Approaches to Studying Drug Responses

New Lipid Guidelines. PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids.

Bridges to Excellence Chronic Obstructive Pulmonary Disease Care Recognition Program Guide

Bridges to Excellence Coronary Artery Disease Care Recognition Program Guide

4/7/ The stats on heart disease. + Deaths & Age-Adjusted Death Rates for

Treating the elderly patients with type 2 diabetes mellitus

Predictive Models for Making Patient Screening Decisions

Dear Clinicians, We welcome you to us your stories directly at or click "Reply" to this . Thank you!

CHRONIC CARE REPORTS. V 9.0, October eclinicalworks, All rights reserved

Treating Hypertension in 2018: What Makes the Most Sense Today?

Int. J. Pharm. Sci. Rev. Res., 36(1), January February 2016; Article No. 06, Pages: JNC 8 versus JNC 7 Understanding the Evidences

NEW GUIDELINES FOR CHOLESTEROL

Hypertension diagnosis (see detail document) Diabetic. Target less than 130/80mmHg

Practical Predictive Analytics. John Cuddeback, MD, PhD AMA IPPS November 11, 2016

Diabetes and the Heart

Placebo-Controlled Statin Trials MANAGEMENT OF HIGH BLOOD CHOLESTEROL MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES

Administrative Consultant for Endocrine Offices

SCIENTIFIC STUDY REPORT

How to Reduce CVD Complications in Diabetes?

Jeffrey Olgin, MD Jeffrey Olgin, MD

WCHQ MEASURES AT A GLANCE

Advances in Alignment, Measurement, and Performance MY 2017 Results Highlights

Inclusion Criteria: 3 years of age and have had at least 2 visits in the last year Exclusion Criteria: BMI 85 th percentile

No relevant financial relationships

Transcription:

Variation in Care Improvement Opportunities Suggests Need for Tailored Clinician-Specific Improvement Interventions Jeffrey P. Anderson, ScD, MPH 1 ; JoAnn M. Sperl-Hillen, MD 1,2 ; A. Lauren Crain, PhD 1 ; Jay R. Desai, PhD 1 ; Pritika C. Kumar, PhD, MPH, MA 1 ; Rebecca C. Rossom, MD, MSCR 1 ; Patrick J. O Connor, MD, MA, MPH 1,2 1 HealthPartners Institute, Minneapolis, MN 2 HealthPartners Center for Chronic Care Innovation, Minneapolis, MN

Conflicts of Interest: Patrick O Connor 2 No funding from industry 11 Current NIH Grants (NHLBI, NIDDK, NICHD, NIA, NIMH, NIDA, NCI, and PCORI) Employed at HealthPartners Institute Co-Director, HealthPartners Center for Chronic Care Innovation Trained in Primary Care, Epidemiology

The Macro-Geography of Care Quality 3 Various organizations including CMS have defined accountability measures that are publicly reported and used to adjust payment for clinical services. There is considerable variation in primary care clinician (PCC) performance on publicly reported accountability measures such as Optimal Diabetes Care (ODC) or Optimal Vascular Care (OVC). In one medical group, ODC across clinics varies from 30% to 55% Within large clinics, ODC varies across PCCs from 20% to 65% Clearly, PCC-specific care improvement opportunities can be identified by looking at these quality measures.

Optimal Diabetes Care (ODC) 4 BP < 140/90 mm Hg A1c < 8% (within 12 months) On Statin Or Statin intolerant On Aspirin Secondary prevention Unless Aspirin intolerant Or Contraindicated Non-smoker

5 Composite Quality Measures: Lump a lot of things together Must be dis-entangled to identify specific strategies to improve care We thus need to look deeper but how much deeper? Let s look at ODC components

When You Go Deeper, You See Care Improvement Opportunities 6 All DOCS Doc A Doc B Doc C ODC (% pts who meet all 5 goals) 48 40 38 40 A1c <8% 71 BP<140/90 85 80 60 Non-Smoker (documented) 84 90 90 On Aspirin (med list) 98 98 98 98 60 85 72 78 80 On Statin (med list) 97 95 85 94 LDL<100 mg/dl** 70 80 60 50

It Gets Complicated.. Need to Go a Little Deeper 7 ODC (% pts who meet all 5 goals) A1c <8% All DOCS Doc A Doc B Doc C 48 71 BP<140/90 85 40 57 38 52 40 47 80 60 85 Non-Smoker (documented) 84 90 90 60 71 On Aspirin (med list) 98 98 98 98 85 72 78 85 80 84 On Statin (med list) 97 95 LDL<100 mg/dl 70 80 85 97 94 60 50

And Even Deeper: Micro-Geography of Care Improvement 8 Rely on CDS algorithms to identify numerator and denominator of multiple metrics. Not just the HTN control rate Profile the specific care processes that must be in place to achieve excellent control of HTN

The Anatomy of Clinical Algorithms 9 As part of a clinical decision support (CDS) system implemented within a large health care delivery system, we developed evidence-based algorithms provided individualized patient treatment recommendations related to optimal management of six major cardiovascular risk factors at adult encounters. As appropriate, we developed process-of-care metrics for each major CV risk factor, such as: recognition of risk factor, timely monitoring of risk factor, time to medication intensification for patients in suboptimal control, medication choices, frequency of drug-condition and drug interaction safety concerns, timely and appropriate referral when indicated, etc.

CV Wizard Clinician View 10

And Even Deeper: 11 Micro-Geography of Care Improvement: Example 1 CDS algorithms necessarily identify both the numerator and the denominator that define specific actionable metrics: Denominator= Number of patients with BP measures that meet criteria for HTN diagnosis Numerator=Number in denominator with no HTN diagnosis

12 The Micro-Geography of Care Improvement: Example 2 CDS algorithms necessarily identify both the numerator and the denominator that define specific actionable metrics: Denominator= Number of patients with elevated BP Numerator=Number in denominator not on any BP meds

The Micro-Geography of Care Improvement: 13 Example 3 CDS algorithms necessarily identify both the numerator and the denominator that define specific actionable metrics: Denominator= Number of patients with elevated BP on 3 or more BP meds Numerator=Number in denominator not on a diuretic

The Micro-Geography of Care Improvement: 14 Example 4 CDS algorithms necessarily identify both the numerator and the denominator that define specific actionable metrics: Denominator= Number of patients with diagnosis of diabetes Numerator=Number in denominator with no A1c test in prior 12 months

Methods 15 We then calculated the proportion of each PCC s patients who might need treatment modification related to that process measure as follows: We defined a set of 60 care improvement opportunities based on CDS algorithms related to control of major CV risk factors including overweight/obesity and glucose. We then quantified variation across 597 PCCs (with a minimum of 20 patients) on these process-of-care measures by analyzing the data from 128,679 clinic visits made by 75,855 adults with diabetes or cardiovascular (CV) risk from January 1, 2017 through December 31, 2017. PCCs were classified by percentile based on the proportion of their eligible patients for whom a specific care improvement opportunity was identified.

Findings 16 When comparing low versus high performing PCCs, we observed substantial variation with as much as a 29% difference in the proportion of patients for whom CDS recommendations were generated. Across measures, low performing providers had a proportion of patients for a CDS recommendation at least 1.9 times greater than high performing providers.

Percentage of Patients who would benefit from 17 specified Care Improvement Opportunities 10 Percentile Median 90 Percentile Meet HTN criteria but no HTN Diagnosis 1.2% 5.3% 11.0% Consider starting a diuretic 5.3% 12.5% 20.5% Increase HTN med dose or add new HTN med 9.6% 20.0% 30.0% Rec combo med to improve adherence (high BP, on 3+ meds) 0% 4.0% 9.3% A1c not done in 12 months 3.1% 9.1% 16.7% Consider metformin start (A1c >goal, GFR >45) 3.6% 8.5% 13.8% A1c >11% T2DM, not on insulin 0% 1.6% 5.0% DM and no UMACR in 12 months 23.8% 37.0% 50.0%

Ratio of Care Opportunity Frequency in 90 th 18 Percentile versus 10 percentile Clinicians Care Improvement Opportunity 90/10 Percentile Meet HTN criteria but no HTN Diagnosis 9.1 Consider starting a diuretic 3.9 Increase HTN med dose or add new HTN med 3.1 Rec combo med to improve adherence (high BP, on 3+ meds) >9 A1c not done in 12 months 5.4 Consider metformin start (A1c >goal, GFR >45) 3.8 A1c >11% T2DM, not on insulin > 5 DM and no UMACR in 12 months 2.1

Percentile Ranks of Primary Care Clinicians A to E across Care Improvement Opportunities 1 to 5. This matrix identifies CIO to target for each PCC (Hypothetical Scenario) PCC Care Improvement Opportunity (CIO) 1 2 3 4 5.30 CIOs to target for each PCC A 90 40 10 92 78 40 1 4 5 B 30 78 90 40 15 80 2 3 30 C 50 55 30 75 40 20 1 2 4 D 45 82 28 36 68 74 2 5 30 E 80 30 74 60 50 10 1 3 4 19

QI Feedback to PCP and their Supervisor, Updated every 2 months Selected Care Improvement Opportunity (CIO) from a set of 30 You re doing better than this % of PCP peers Number of Patients evaluated in past 2 months % of Your Patients with Opportunity to Improve Care You Now Your Goal* Use thiazide diuretics 8 50 38% 23% 11 24 35% 28% Initiate statin treatment when indicated Refer smokers to 14 23 24% 16% cessation programs Hypertension recognition 71 61 12% Great Job! Screening for diabetes when indicated 83 33 9% Great Job! Aspirin underuse 94 17 8% Great Job! HealthPartners *This is performance level of median PCP 20 20

Limitations 21 One clinical delivery system; only primary care; mostly physicians with few NP/PA Data predated last HTN Guideline change Results Are Preliminary; Analysis Ongoing Needs adjustment for patient mix Depends upon accuracy and completeness of EMR data: meds, labs, diagnoses, other Some PCCs have few patients in specific subgroups (A1c >11%, BP >180/110)

Conclusions/Implications 22 In a care delivery system frequently recognized for high quality care, we observed substantial variation in frequency of care improvement opportunities across PCCs within and across clinics. PCC-specific patterns of care improvement opportunities could guide deployment of tailored and efficient care improvement interventions to improve care. The dissemination potential for this method of mapping the Micro-Geography of care Improvement is high.

Thank you! Patrick O Connor patrick.j.oconnor@healthpartners.com